Activation of nicotinic α7 acetylcholine receptor enhances long term potentation in wild type mice but not in APPswe/PS1ΔE9 mice

Neuroscience Letters

Volumn 487, Issue 3, 2011, Pages 325-329

  Söderman, Andreas ^a   Mikkelsen, Jens D ^b,c   West, Mark J ^a   Christensen, Ditte Z ^b   Jensen, Morten S ^a  

^a AARHUS UNIVERSITY   (Denmark)

^b Rigshospitalet   (Denmark)

^c NEUROSEARCH A S   (Denmark)

Author keywords

7 nAChR; A ; APPswe PS1 E9 mice; LTP

Indexed keywords

1,4 DIAZABICYCLO[3.2.2]NONANE 4 CARBOXYLIC ACID 4 BROMOPHENYL ESTER; AMYLOID BETA PROTEIN; BUNGAROTOXIN RECEPTOR; NICOTINE;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN SLICE; CONCENTRATION RESPONSE; CONTROLLED STUDY; HIPPOCAMPUS; LONG TERM POTENTIATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING;

AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BICYCLO COMPOUNDS, HETEROCYCLIC; EXCITATORY POSTSYNAPTIC POTENTIALS; FEMALE; HIPPOCAMPUS; HUMANS; LONG-TERM POTENTIATION; MICE; MICE, TRANSGENIC; NICOTINE; NICOTINIC AGONISTS; ORGAN CULTURE TECHNIQUES; RECEPTORS, NICOTINIC; RIBOSOMAL PROTEINS; RNA-BINDING PROTEINS;

EID: 78650521407     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2010.10.049     Document Type: Article

References (28)

1. Biton B., Bergis O.E., Galli F., Nedelec A., Lochead A.W., Jegham S., Godet D., Lanneau C., Santamaria R., Chesney F., Léonardon J., Granger P., Debono M.W., Bohme G.A., Sgard F., Besnard F., Graham D., Coste A., Oblin A., Curet O., Vigé X., Voltz C., Rouquier L., Souilhac J., Santucci V., Gueudet C., Françon D., Steinberg R., Griebel G., Oury-Donat F., George P., Avenet P., Scatton B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profile. Neuropsychopharmacology 2007, 32:1-16.
2. Cincotta S.L., Yorek M.S., Moschak T.M., Lewis S.R., Rodefer J.S. Selective nicotinic acetylcholine receptor agonists: potential therapies for neuropsychiatric disorders with cognitive dysfunction. Curr. Opin. Investig. Drugs 2008, 9:47-56.
3. Eriksen J.L., Janus C.G. Plaques, tangles, and memory loss in mouse models of neurodegeneration. Behav. Genet. 2007, 37:79-100.
4. Fujii S., Ji Z., Morita N., Sumikawa K. Acute and chronic nicotine exposure differentially facilitate the induction of LTP. Brain Res. 1999, 846:137-143.
5. Games D., Adams D., Alessandrini R., Barbour R., Berthelette P., Blackwell C., Carr T., Clemens J., Donaldson T., Gillespie F., Guido T., Hagopian S., Johnson-Wood K., Lee M., Leibowitz P., Lieberburg I., Little S., Masliah E., McConlogue L., Montoya-Zavala M., Mucke L., Paganini L., Penniman E., Power M., Schenk D., Seubert P., Snyder B., Soriano F., Tan H., Vitale J., Wadsworth S., Wolozin B., Zhao J. Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein. Nature 1995, 373:523-527.
6. Gordon M.N., Holcomb L.A., Jantzen P.T., DiCarlo G., Wilcock D., Boyett K.W., Connor K., Melachrino J., O'Callaghan J.P., Morgan D. Time course of the development of Alzheimer-like pathology in the doubly transgenic PS1+APP mouse. Exp. Neurol. 2002, 173:183-195.
7. Guan Z.Z., Zhang X., Ravid R., Nordberg A. Decreased protein levels of nicotinic receptor subunits in the hippocampus and temporal cortex of patients with Alzheimer's disease. J. Neurochem. 2000, 74:237-243.
8. Hashimoto K., Ishima T., Fujita Y., Matsuo M., Kobashi T., Takahagi M., Tsukada H., Iyo M. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the novel selective alpha7 nicotinic receptor agonist SSR180711. Biol. Psychiatry 2008, 63:92-97.
9. Hunter B.E., de Fiebre C.M., Papke R.L., Kem W.R., Meyer E.M. A novel nicotinic agonist facilitates induction of long-term potentiation in the rat hippocampus. Neurosci. Lett. 1994, 168:130-134.
10. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neurophil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol. 1997, 56:965-973.
11. Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., Younkin S.G., Borchelt D.R. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004, 13:159-170.
12. Jones S., Sudweeks S., Yakel J.L. Nicotinic receptors in the brain: correlating physiology with function. Trends Neurosci. 1999, 22:555-561.
13. Liu Q., Kawai H., Berg D.K. beta-amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:4734-4739.
14. Matsuyama S., Matsumoto A., Enomoto T., Nishizaki T. Activation of nicotinic acetylcholine receptors induces long-term potentiation in vivo in the intact mouse dentate gyrus. Eur. J. Neurosci. 2000, 12:3741-3747.
15. Nagele R.G., D'Andrea M.R., Anderson W.J., Wang H.Y. Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience 2002, 110:199-211.
16. Newhouse P.A., Potter A., Singh A. Effects of nicotinic stimulation on cognitive performance. Curr. Opin. Pharmacol. 2004, 4:36-46.
17. Pettit D.L., Shao Z., Yakel J.L. Beta-amyloid(1-42) peptide directly modulates nicotinic receptors in the rat hippocampal slice. J. Neurosci. 2001, 21:RC120.
18. Pichat P., Bergis O.E., Terranova J.P., Urani A., Duarte C., Santucci V., Gueudet C., Voltz C., Steinberg R., Stemmelin J., Oury-Donat F., Avenet P., Griebel G., Scatton B. SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (II) efficacy in experimental models predictive of activity against cognitive symptoms of schizophrenia. Neuropsychopharmacology 2007, 32:17-34.
19. Reiserer R.S., Harrison F.E., Syverud D.C., McDonald M.P. Impaired spatial learning in the APPSwe+PSEN1DeltaE9 bigenic mouse model of Alzheimer's disease. Genes Brain Behav. 2007, 6:54-65.
20. Sawada S., Yamamoto C., Ohno-Shosaku T. Long-term potentiation and depression in the dentate gyrus, and effects of nicotine. Neurosci. Res. 1994, 20:323-329.
21. Seguela P., Wadiche J., Dineley-Miller K., Dani J.A., Patrick J.W. Molecular cloning, functional properties, and distribution of rat brain alpha 7: a nicotinic cation channel highly permeable to calcium. J. Neurosci. 1993, 13:596-604.
22. Søderman A., Thomsen M.S., Hansen H.H., Nielsen E.Ø., Jensen M.S., West M.J., Mikkelsen J.D. The nicotinic alpha7 acetylcholine receptor agonist ssr180711 is unable to activate limbic neurons in mice overexpressing human amyloid-beta 1-42. Brain Res. 2008, 1227:240-247.
23. Thomsen M.S., Christensen D.Z., Hansen H.H., Redrobe J.P., Mikkelsen J.D. Alpha(7) nicotinic acetylcholine receptor activation prevents behavioral and molecular changes induced by repeated phencyclidine treatment. Neuropharmacology 2009, 56:1001-1009.
24. Volianskis A., Kostner R., Molgaard M., Hass S., Jensen M.S. Episodic memory deficits are not related to altered glutamatergic synaptic transmission and plasticity in the CA1 hippocampus of the APPswe/PS1DeltaE9-deleted transgenic mice model of beta-amyloidosis. Neurobiol. Aging 2008, (Epub ahead of print).
25. Wang H.Y., Lee D.H., D'Andrea M.R., Peterson P.A., Shank R.P., Reitz A.B. Beta-amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J. Biol. Chem. 2000, 275:5626-5632.
26. Wang H.Y., Lee D.H., Davis C.B., Shank R.P. Amyloid peptide A beta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J. Neurochem. 2000, 75:1155-1161.
27. Welsby P.J., Rowan M.J., Anwyl R. Beta-amyloid blocks high frequency stimulation induced LTP but not nicotine enhanced LTP. Neuropharmacology 2007, 53:188-195.
28. West M.J., Bach G., Soderman A., Jensen J.L. Synaptic contact number and size in stratum radiatum CA1 of APP/PS1DeltaE9 transgenic mice. Neurobiol. Aging 2009, 30:1756-1776.